Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01100437 · ClinicalTrials.gov registry record · Phase 4
Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients
A Phase 4 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT01100437 is a Phase 4 study that was terminated before completion, run by Pfizer. The registered enrollment target is 14 participants.
The verdict
NCT01100437, a Phase 4 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will evaluate whether crushed EMBEDA capsules induce clinical opiate withdrawal signs and symptoms in opioid-dependent patients with chronic non-cancer pain who are stabilized on EMBEDA.
Interventions
- DRUG EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush
- DRUG EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01100437
The ClinicalTrials.gov registry entry for NCT01100437 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush is the first listed.
NCT01100437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01100437 about?
NCT01100437 is a clinical study titled "Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients". This study will evaluate whether crushed EMBEDA capsules induce clinical opiate withdrawal signs and symptoms in opioid-dependent patients with chronic non-cancer pain who are stabilized on EMBEDA.
What is the current status of trial NCT01100437?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2010-04. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01100437?
The interventions under investigation include: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush (DRUG), EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole (DRUG).
Who is sponsoring clinical trial NCT01100437?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.